Crowdonomics
All companies
CANINE BIOLOGICS logo

CANINE BIOLOGICS

Operating

Canine Life Sciences Inc.

Founded 2019

Visit website

Our 2021 expansion brings breakthrough nutrition to more dogs with cancer

Post-money valuation ⓘ
$6.2M
As of Apr 2022 · from Canine Biologics Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$96,712
Across 2 rounds since 2021
Latest share price
$0.81
Canine Biologics Common Stock 1 offering price

Financials

FY2019–FY2022 · from SEC filings · hover any figure for its source
$0
−$10K
2019
2020
$6K
−$354K
2021
$49K
−$449K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
FY2022
Income statement
Revenue
$0
—
$5,823
$49,391
Cost of goods sold
$0
—
$5,650
$72,559
Gross margin
—
—
3%
-47%
Net income
-$10,497
—
-$353,517
-$449,310
Taxes paid
$0
—
$0
$0
Balance sheet
Cash
$119,551
—
$98,886
$24,684
Accounts receivable
$0
—
$25,894
$11,110
Total assets
$146,911
—
$404,133
$159,970
Short-term debt
$8,409
—
$19,100
$66,000
Long-term debt
$0
—
$0
$0
Total liabilities
$8,409
—
$19,100
$66,000
Other
Headcount
—
5
—
5

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$6.5M
Valuation cap
$6.2M
post-money
CANINE BIOLOGICS SAFE 1
Canine Biologics Common Stock 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Canine Biologics Common Stock 1ClosedReg CF · Common Equity · via Netcapital
Raised $39.1K / $477.5KPost-money $6.2M
CANINE BIOLOGICS SAFE 1ClosedReg CF · SAFE · via WeFunder
Raised $57.6K / $1.1MInvestors 26Valuation cap $6.5M

Team

2 people
Charles Mueller
Principal Financial Officer
Jeff Sutherland
Principal Executive Officer

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 1 of 5 annual reports (FY2021–FY2025)

26 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-ARMar 21, 20220001669191-22-000235
    EDGAR
  • Form C-UMar 17, 20220001669191-22-000233
    EDGAR
  • Form C/ANov 19, 20210001669191-21-001148
    EDGAR
  • Form C/AOct 1, 20210001669191-21-001002
    EDGAR
  • Form C/ASep 24, 20210001669191-21-000955
    EDGAR
  • Form C/ASep 10, 20210001669191-21-000875
    EDGAR
  • Form CSep 9, 20210001669191-21-000873
    EDGAR
  • Form CMay 5, 20210001670254-21-000639
    EDGAR
Source: ManualCIK 0001857342Share price $0.81

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.